Data Highlight Potential of SAGE-217 to Address Acute and Chronic Forms of Epilepsy and Seizure Disorders September 2, 2014 SAGE Therapeutics today presented preclinical data …
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy
July 2, 2014 Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that …
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome
June 25, 2014 Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that …
FDA Issues Complete Response Letter for PLUMIAZ™, Investigational Medicine for Epilepsy Cluster Seizures
Acorda Therapeutics Committed to Working with FDA May 2nd, 2014 Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued …
Courtagen to Provide Genetic Profiling of Children with Intractable Epilepsy to Support Clinical Developments with Cannabidiol
Using the latest next-generation sequencing technologies, Courtagen is collaborating with various academic centers and US physicians to profile the genomes of intractable epilepsy patients to …
Lundbeck receives FDA approval for Epilepsy Intravenous Carbamazepine
FDA Accepts Lundbeck Submission of New Drug Application for Intravenous Carbamazepine March 10, 2014 Lundbeck LLC today announced that the U.S. Food and Drug Administration …